Crocker J F, Renton K W, LeVatte T L, McLellan D H
Department of Pediatrics, Dalhousie University, IWK Hospital, Nova Scotia, Canada.
Pediatr Nephrol. 1994 Aug;8(4):408-11. doi: 10.1007/BF00856514.
The elimination of cyclosporin A was assessed in eight pediatric renal transplant patients who received calcium channel blockers concomitantly with their immunosuppressive therapy. In three children, verapamil decreased the rate of elimination of cyclosporin A. In five children who received nifedipine, cyclosporin A elimination was also impaired, which contrasts with the reports in adult patients indicating that this calcium channel blocker has no effect on cyclosporin A elimination. When both calcium channel blockers were used on separate occasions in the same patient, nifedipine was less potent than verapamil in depressing cyclosporin A elimination. Although the number of subjects studied is small, these results likely indicate that nifedipine, as well as other calcium channel blocking drugs, must be used with caution in pediatric renal transplant patients.
在八名接受免疫抑制治疗同时服用钙通道阻滞剂的儿科肾移植患者中评估了环孢素A的消除情况。在三名儿童中，维拉帕米降低了环孢素A的消除率。在五名服用硝苯地平的儿童中，环孢素A的消除也受到损害，这与成人患者的报告形成对比，成人报告表明这种钙通道阻滞剂对环孢素A的消除没有影响。当在同一患者的不同时间分别使用这两种钙通道阻滞剂时，硝苯地平在抑制环孢素A消除方面的效力低于维拉帕米。尽管研究的受试者数量较少，但这些结果可能表明，硝苯地平以及其他钙通道阻滞剂在儿科肾移植患者中必须谨慎使用。
